Trial Profile
Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms RAPA
- 31 Jul 2012 Results published in Diabetologia.
- 24 Mar 2012 Actual number of patients changed from 40 to 35 as reported by ClinicalTrials.gov.
- 30 Jun 2010 New trial record